Alessandra Di Franco
Overview
Explore the profile of Alessandra Di Franco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cantini G, Di Franco A, Mannelli M, Scime A, Maggi M, Luconi M
Front Cell Dev Biol
. 2020 Jun;
8:332.
PMID: 32478073
Adipose tissue in physiological and in metabolically altered conditions (obesity, diabetes, metabolic syndrome) strictly interacts with the developing tumors both systemically and locally. In addition to the cancer-associated fibroblasts, adipose...
2.
Cantini G, Trabucco M, Di Franco A, Mannucci E, Luconi M
J Mol Endocrinol
. 2019 Sep;
63(4):249-260.
PMID: 31525727
Glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are currently used for the treatment of type 2 diabetes, have recently been proposed as anti-obesity drugs, due to their relevant effects on...
3.
Cantini G, Di Franco A, Mannucci E, Luconi M
Int J Cardiol
. 2018 Mar;
257:38.
PMID: 29506737
No abstract available.
4.
Salvianti F, Canu L, Poli G, Armignacco R, Scatena C, Cantini G, et al.
Oncotarget
. 2017 Oct;
8(39):65525-65533.
PMID: 29029450
Adrenocortical cancer (ACC) is a rare aggressive malignancy. Recent ACC integrated genomics analysis contributed to redefine the risk groups on molecular basis, including tumor microRNAs (miRs), detectable also in the...
5.
Samavat J, Cantini G, Lotti F, Di Franco A, Tamburrino L, DeglInnocenti S, et al.
Obes Surg
. 2017 Jul;
28(1):69-76.
PMID: 28702741
Objectives: The aim of this study is to evaluate the effect of massive weight loss on the seminal parameters at 6 months from bariatric surgery. Design: Two-armed prospective study performed...
6.
Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, et al.
Int J Cardiol
. 2017 May;
243:86-90.
PMID: 28526540
Background: Empagliflozin is reported to reduce cardiovascular mortality and the rate of hospitalization for heart failure in type 2 diabetic patients with prior cardiovascular events. The mechanisms underlying the cardiac...
7.
Cantini G, Di Franco A, Mannucci E, Luconi M
Mol Cell Endocrinol
. 2016 Nov;
439:10-15.
PMID: 27746194
Glucagon-like peptide 1(9-36) [GLP-1(9-36)] is generated by dipeptidyl peptidase-4 (DPP4) cleavage of the gut incretin hormone, GLP-1(7-36). Since GLP-1(9-36) has a very low affinity for the GLP-1 receptor (GLP-1R), it...
8.
Di Franco A, Guasti D, Squecco R, Mazzanti B, Rossi F, Idrizaj E, et al.
Stem Cells
. 2016 Feb;
34(6):1679-91.
PMID: 26866833
The potential therapeutic applications of targeting brown adipose tissue open new clinical avenues in fighting against metabolic pathologies. However, due to the limited extension in adult humans of brown depots,...
9.
Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M
Mol Cell Endocrinol
. 2015 Jan;
402:43-50.
PMID: 25575456
Glucagon-Like Peptide-1 (GLP-1) receptor agonists, used as glucose-lowering drugs, also induce weight loss by inhibiting food intake. The present study was aimed at the assessment of the in vitro effects...
10.
Samavat J, Natali I, DeglInnocenti S, Filimberti E, Cantini G, Di Franco A, et al.
Fertil Steril
. 2014 Sep;
102(5):1274-1281.e2.
PMID: 25226854
Objective: To compare spontaneous (Sp-AR) and P-induced acrosome reaction (AR) in spermatozoa of obese and lean subjects. Setting: Bariatric unit at a university hospital. Design: Prospective, observational study. Patient(s): Twenty-three...